Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults

This study has been completed.
Information provided by (Responsible Party):
University of Utah Identifier:
First received: April 15, 2010
Last updated: November 14, 2011
Last verified: November 2011

The goals of our study are to critically evaluate if a healthy population supplemented with Transfer factor experiences fewer incidences of colds and flu, or experience shorter duration of illness compared to an identical population taking placebo. In this study we will give either Transfer factor or a placebo to two groups of healthy adult men and women for a period of 7 weeks in a double-blind experimental design. The frequency and duration of colds and flu-like symptoms will be recorded during the course of the study. Saliva samples will be collected weekly and assessed for salivary IgA secretion rate. Data from this study will establish the efficacy of Transfer Factor to support a healthy immune system.

Condition Intervention
Upper Respiratory Tract Infections Due to Influenza or Rhinovirus
Dietary Supplement: transfer factor
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Double Blind Study on the Efficacy of a Colostrum and Egg Yolk Supplement vs. Placebo to Reduce Frequency and Duration of Upper Respiratory Tract Infections in Healthy Adults

Resource links provided by NLM:

Further study details as provided by University of Utah:

Enrollment: 49
Study Start Date: January 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Transfer Factor
Transfer factor supplement; 2 capsules per day
Dietary Supplement: transfer factor
capsules, 2 per day by mouth for 7 weeks.
Placebo Comparator: Sugar pill Dietary Supplement: Placebo
cornstarch, 2 capsules per day by mouth.


Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males and females (18 - 40) who are in good health

Exclusion Criteria:

  • Subjects who are allergic to eggs (on which the supplement is based). If a volunteer is not sure if they are allergic to eggs or milk. Those who are currently smoking, have cardiovascular disease, cancer, diabetes, liver disease, renal insufficiency, any chronic disease that might interfere with study participation, BMI above 40 kg/m2, consumption of >12 alcoholic drinks weekly, or unwillingness to stop current supplement intake. Women who are pregnant or lactating will also be excluded from the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01106183

United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
University of Utah
  More Information

No publications provided

Responsible Party: University of Utah Identifier: NCT01106183     History of Changes
Other Study ID Numbers: 38766 4Life-Transfer Factor
Study First Received: April 15, 2010
Last Updated: November 14, 2011
Health Authority: United States: University of Utah Institutional Review Board

Additional relevant MeSH terms:
Communicable Diseases
Respiratory Tract Infections
Respiratory Tract Diseases processed this record on November 25, 2014